- Home
- SILO vs APVO Comparison
SILO vs APVO Comparison
Compare SILO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- APVO
- Stock Information
- Founded
- SILO 2010
- APVO 2016
- Country
- SILO United States
- APVO United States
- Employees
- SILO N/A
- APVO N/A
- Industry
- SILO Apparel
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- APVO Health Care
- Exchange
- SILO Nasdaq
- APVO Nasdaq
- Market Cap
- SILO 4.5M
- APVO 4.1M
- IPO Year
- SILO N/A
- APVO N/A
- Fundamental
- Price
- SILO $0.61
- APVO $3.01
- Analyst Decision
- SILO
- APVO Strong Buy
- Analyst Count
- SILO 0
- APVO 1
- Target Price
- SILO N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- SILO 316.2K
- APVO 6.7M
- Earning Date
- SILO 08-12-2025
- APVO 08-07-2025
- Dividend Yield
- SILO N/A
- APVO N/A
- EPS Growth
- SILO N/A
- APVO N/A
- EPS
- SILO N/A
- APVO N/A
- Revenue
- SILO $72,102.00
- APVO N/A
- Revenue This Year
- SILO $1.86
- APVO N/A
- Revenue Next Year
- SILO N/A
- APVO N/A
- P/E Ratio
- SILO N/A
- APVO N/A
- Revenue Growth
- SILO N/A
- APVO N/A
- 52 Week Low
- SILO $0.41
- APVO $2.81
- 52 Week High
- SILO $4.50
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- SILO 48.15
- APVO 36.72
- Support Level
- SILO $0.60
- APVO $2.89
- Resistance Level
- SILO $0.64
- APVO $3.19
- Average True Range (ATR)
- SILO 0.04
- APVO 0.93
- MACD
- SILO 0.01
- APVO 0.25
- Stochastic Oscillator
- SILO 48.98
- APVO 2.95
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.